Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (140)	4/20/1999 8:19:00 AM
From: Jim Oravetz	Respond to of 370

Mentions Vion to present at a conference in July. Message 8952640 Jim

To: Jim Oravetz who wrote (140)	4/24/1999 9:11:00 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 370

Vion completes $4M private stock sale 04/24/1999 By By Register Staff NEW HAVEN - Vion Pharmaceuticals Inc. has completed a $4 million private stock sale to finance research and development, the firm said Friday. Vion said it has received $750,000 from a group of investors headed by Kleinwort Benson LTD, a subsidiary of Dresdner Kleinwort Benson and Winchester Capital Healthcare Partners LLC. Last week, the New Haven-based biopharmaceutical firm announced a $3.25 million sale of private stock to another group of investors. Vion shares trade on the Nasdaq exchange. under the VION ticker symbol. They fell slightly Friday to $5.53, down 3 cents. The firm, based in New Haven's Science Park, researches and develops treatments for cancer and viral diseases. One cancer-fighting drug Vion has developed, Promycin, is in Phase III clinical trials, one of the last hurdles a drug must clear before introduction to the general public. Jim